G
Guardant Health D
D
GH
42.030
USD
-1.46
(-3.36%)
قبل الجلسة
حجم التداول
60
الربح لكل سهم
-3
العائد الربحي
-
P/E
-12
حجم السوق
5,187,403,165
العنوان: Guardant Health
القطاع: Healthcare
الصناعة: Diagnostics & Research
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD,test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.